You just read:

Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma

News provided by

Mirati Therapeutics, Inc.

Aug 11, 2014, 08:00 ET